224 related articles for article (PubMed ID: 37066788)
1. Design and Rationale the SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study.
Ruberg FL; Blaner WS; Chiuzan C; Connors LH; Einstein AJ; Fine D; Helmke S; Kurian D; Pandey S; Raiszadeh F; Rodriguez C; Sabogal N; Teruya S; Winburn M; Chung WK; Cohn E; Miller EJ; Kelly JW; Maurer MS
J Am Heart Assoc; 2023 Apr; 12(8):e028534. PubMed ID: 37066788
[TBL] [Abstract][Full Text] [Related]
2. Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study.
Madhani A; Sabogal N; Massillon D; Paul LD; Rodriguez C; Fine D; Helmke S; Winburn M; Kurian D; Raiszadeh F; Teruya S; Cohn E; Einstein AJ; Miller EJ; Connors LH; Maurer MS; Ruberg FL
J Am Heart Assoc; 2023 Aug; 12(15):e028973. PubMed ID: 37486082
[TBL] [Abstract][Full Text] [Related]
3. Relation of Body Mass Index to Transthyretin Cardiac Amyloidosis Particularly in Black and Hispanic Patients (from the SCAN-MP Study).
Poterucha TJ; Kurian D; Raiszadeh F; Teruya S; Elias P; Kogan R; Chiuzan C; Einstein AJ; Ruberg FL; Maurer MS
Am J Cardiol; 2022 Aug; 177():116-120. PubMed ID: 35705430
[TBL] [Abstract][Full Text] [Related]
4. Cardiac Amyloidosis Due to Transthyretin Protein: A Review.
Ruberg FL; Maurer MS
JAMA; 2024 Mar; 331(9):778-791. PubMed ID: 38441582
[TBL] [Abstract][Full Text] [Related]
5. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
Porcari A; Razvi Y; Masi A; Patel R; Ioannou A; Rauf MU; Hutt DF; Rowczenio D; Gilbertson J; Martinez-Naharro A; Venneri L; Whelan C; Lachmann H; Wechalekar A; Quarta CC; Merlo M; Sinagra G; Hawkins PN; Fontana M; Gillmore JD
Eur J Heart Fail; 2023 Apr; 25(4):515-524. PubMed ID: 36644836
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of systematic screening and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in patients with heart failure with preserved ejection fraction (HFpEF) in United States.
Lau ATC; DiDomenico RJ; Kim K
Int J Cardiol; 2024 Mar; 398():131598. PubMed ID: 37979789
[TBL] [Abstract][Full Text] [Related]
7. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy.
Maestro-Benedicto A; Vela P; de Frutos F; Mora N; Pomares A; Gonzalez-Vioque E; Briceño A; Cabrera E; Cobo-Marcos M; Dominguez F; Gonzalez-Lopez E; Segovia J; Lara-Pezzi E; Garcia-Pavia P
Eur J Heart Fail; 2022 Dec; 24(12):2367-2373. PubMed ID: 35999650
[TBL] [Abstract][Full Text] [Related]
8. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).
Maurer MS; Hanna M; Grogan M; Dispenzieri A; Witteles R; Drachman B; Judge DP; Lenihan DJ; Gottlieb SS; Shah SJ; Steidley DE; Ventura H; Murali S; Silver MA; Jacoby D; Fedson S; Hummel SL; Kristen AV; Damy T; Planté-Bordeneuve V; Coelho T; Mundayat R; Suhr OB; Waddington Cruz M; Rapezzi C;
J Am Coll Cardiol; 2016 Jul; 68(2):161-72. PubMed ID: 27386769
[TBL] [Abstract][Full Text] [Related]
9. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
10. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
Miller AB; Januzzi JL; O'Neill BJ; Gundapaneni B; Patterson TA; Sultan MB; López-Sendón J
Am J Cardiol; 2021 Jun; 148():146-150. PubMed ID: 33667442
[TBL] [Abstract][Full Text] [Related]
11. Counseling Family Members and Monitoring for Evidence of Disease in Asymptomatic Carriers of Amyloid Transthyretin Cardiac Amyloidosis.
Barker N; Judge DP
Am J Cardiol; 2022 Dec; 185 Suppl 1():S43-S50. PubMed ID: 36216601
[TBL] [Abstract][Full Text] [Related]
12. Association of the V122I Hereditary Transthyretin Amyloidosis Genetic Variant With Heart Failure Among Individuals of African or Hispanic/Latino Ancestry.
Damrauer SM; Chaudhary K; Cho JH; Liang LW; Argulian E; Chan L; Dobbyn A; Guerraty MA; Judy R; Kay J; Kember RL; Levin MG; Saha A; Van Vleck T; Verma SS; Weaver J; Abul-Husn NS; Baras A; Chirinos JA; Drachman B; Kenny EE; Loos RJF; Narula J; Overton J; Reid J; Ritchie M; Sirugo G; Nadkarni G; Rader DJ; Do R
JAMA; 2019 Dec; 322(22):2191-2202. PubMed ID: 31821430
[TBL] [Abstract][Full Text] [Related]
13. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
Yadav JD; Othee H; Chan KA; Man DC; Belliveau PP; Towle J
Ann Pharmacother; 2021 Dec; 55(12):1502-1514. PubMed ID: 33685242
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
Elliott P; Drachman BM; Gottlieb SS; Hoffman JE; Hummel SL; Lenihan DJ; Ebede B; Gundapaneni B; Li B; Sultan MB; Shah SJ
Circ Heart Fail; 2022 Jan; 15(1):e008193. PubMed ID: 34923848
[TBL] [Abstract][Full Text] [Related]
15. The Association of Cardiac Biomarkers, the Intensity of Tc99 Pyrophosphate Uptake, and Survival in Patients Evaluated for Transthyretin Cardiac Amyloidosis in the Early Therapeutics Era.
Martyn T; Saef J; Hussain M; Ives L; Kiang A; Estep JD; Collier P; Starling RC; Cremer PC; Tang WHW; Hanna M; Jaber WA
J Card Fail; 2022 Oct; 28(10):1509-1518. PubMed ID: 35843490
[TBL] [Abstract][Full Text] [Related]
16. ATTR Epidemiology, Genetics, and Prognostic Factors.
Obi CA; Mostertz WC; Griffin JM; Judge DP
Methodist Debakey Cardiovasc J; 2022; 18(2):17-26. PubMed ID: 35414855
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Pitfall and Clinical Characteristics of Variant Versus Wild-Type Transthyretin Amyloid Cardiomyopathy in Asian Population: The Korean Nationwide Cohort Study.
Kim D; Youn JC; Lee HW; Oh J; Son JW; Cho HJ; Lee S; Shah NR; Kittleson MM; Jeon ES
J Korean Med Sci; 2024 May; 39(19):e163. PubMed ID: 38769922
[TBL] [Abstract][Full Text] [Related]
18. Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model.
Arvanitis M; Koch CM; Chan GG; Torres-Arancivia C; LaValley MP; Jacobson DR; Berk JL; Connors LH; Ruberg FL
JAMA Cardiol; 2017 Mar; 2(3):305-313. PubMed ID: 28196196
[TBL] [Abstract][Full Text] [Related]
19. Deep phenotyping of p.(V142I)-associated variant transthyretin amyloid cardiomyopathy: Distinct from wild-type transthyretin amyloidosis?
Razvi Y; Ioannou A; Patel RK; Chacko L; Karia N; Riefolo M; Porcari A; Rauf MU; Starr N; Ganesananthan S; Blakeney I; Kaza N; Filisetti S; Bolhuis RE; Rowczenio D; Gilbertson J; Hutt D; Mahmood S; Lachmann HJ; Wechalekar AD; Kotecha T; Knight DS; Coghlan JG; Petrie A; Whelan CJ; Venneri L; Martinez-Naharro A; Hawkins P; Fontana M; Gillmore JD
Eur J Heart Fail; 2024 Feb; 26(2):383-393. PubMed ID: 37953725
[TBL] [Abstract][Full Text] [Related]
20. Racial Differences in Val122Ile-Associated Transthyretin Cardiac Amyloidosis.
Batra J; Rosenblum H; Cappelli F; Zampieri M; Olivotto I; Griffin JM; Saith SE; Teruya S; De Los Santos J; Argiro A; Burkhoff D; Perfetto F; Maurer MS
J Card Fail; 2022 Jun; 28(6):950-959. PubMed ID: 34974181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
